Trial Profile
Phase III,Open-label,Prospective,Two-armed,Multicenter Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms ZEAL
- Sponsors Biogen; Cell Therapeutics; CTI BioPharma
- 27 Jul 2019 Status changed from active, no longer recruiting to discontinued.
- 19 Jun 2019 This trial has been Discontinued in Finland , according to European Clinical Trials Database
- 14 Jul 2009 Bayer added as trial sponsor as reported by ClinicalTrials.gov.